Annals of Surgery

Skip Navigation LinksHome > December 2012 - Volume 256 - Issue 6 > Long-Term Outcomes of the Australasian Randomized Clinical T...
Annals of Surgery:
doi: 10.1097/SLA.0b013e3182765ff8
Randomized Controlled Trial

Long-Term Outcomes of the Australasian Randomized Clinical Trial Comparing Laparoscopic and Conventional Open Surgical Treatments for Colon Cancer: The Australasian Laparoscopic Colon Cancer Study Trial

Bagshaw, Philip F. FRACS*; Allardyce, Randall A. PhD*; Frampton, Christopher M. PhD; Frizelle, Francis A. FRACS*; Hewett, Peter J. FRACS§¶; McMurrick, Paul J. FRACS; Rieger, Nicholas A. FRACS§¶; Smith, J. Shona MA; Solomon, Michael J. FRACS#; Stevenson, Andrew RL. FRACS**; the Australasian Laparoscopic Colon Cancer Study Group

Collapse Box


Objective: We report a multicentered randomized controlled trial across Australia and New Zealand comparing laparoscopic-assisted colon resection (LCR) with open colon resection (OCR) for colon cancer.

Background: Colon cancer is a significant worldwide health issue. This trial investigated whether the short-term benefits associated with LCR for colon cancer could be achieved safely, without survival disadvantages, in our region.

Methods: A total of 601 patients with potentially curable colon cancer were randomized to receive LCR or OCR. Primary endpoints were 5-year overall survival, recurrence-free survival, and freedom from recurrence rates, compared using an intention-to-treat analysis.

Results: On April 5, 2010, 587 eligible patients were followed for a median of 5.2 years (range, 1 week–11.4 years) with 5-year confirmed follow-up data for survival and recurrence on 567 (96.6%). Significant differences between the 2 trial groups were as follows: LCR patients were older at randomization, and their pathology specimens showed smaller distal resection margins; OCR patients had some worse pathology parameters, but there were no differences in disease stages. There were no significant differences between the LCR and OCR groups in 5-year follow-up of overall survival (77.7% vs 76.0%, P = 0.64), recurrence-free survival (72.7% vs 71.2%, P = 0.70), or freedom from recurrence (86.2% vs 85.6%, P = 0.85).

Conclusions: In spite of some differences in short-term surrogate oncological markers, LCR was not inferior to OCR in direct measures of survival and disease recurrence. These findings emphasize the importance of long-term data in formulating evidence-based practice guidelines.

© 2012 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.